Eli Lilly (LLY) officially joined the elite group of U.S. companies valued at more than $1T on Friday, becoming the tenth American stock to currently cross the landmark threshold.
The move came as shares advanced 1%, driven by persistent investor enthusiasm for the pharmaceutical giant’s fast-growing GLP-1 drug franchise, which continues to reshape expectations across the broader health care sector.
Despite achieving the trillion-dollar milestone, Lilly (LLY) does not currently rank among Seeking Alpha’s top ten healthcare stocks based on its Quant Ratings framework.
According to the SA’s proprietary scoring system, LLY holds a Quant Rating of 3.47, placing it outside the upper tier. Below is a breakdown of the highest-rated healthcare names as measured by Seeking Alpha’s Quant Grades (note that these are only companies with a market cap of $10B and above):
No. 1: Guardant Health (GH), Quant Rating of 4.95.
No. 2: Incyte Corporation (INCY), Quant Rating of 4.93.
No. 3: Pfizer (PFE), Quant Rating of 4.91.
No. 4: Merck & Co. (MRK), Quant Rating of 4.87.
No. 5: Roivant Sciences Ltd. (ROIV), Quant Rating of 4.82.
No. 6: Vertex Pharmaceuticals (VRTX), Quant Rating of 4.70.
No. 7: Astellas Pharma Inc. (OTCPK:ALPMY), Quant Rating of 4.69.
No. 8: Illumina (ILMN), Quant Rating of 4.62.
No. 9: Neurocrine Biosciences (NBIX), Quant Rating of 4.58.
No. 10: Exelixis, Inc. (EXEL), Quant Rating of 4.58.
For more on the healthcare space, investors can look to gain diversified exposure to the space through exchange-traded funds.
Health Care ETFs: (XLV), (VHT), (IHI), (IXJ), (IYH), (FHLC), (FXH), (IBB), (XBI), (FBT), (BBH), (PBE), (IDNA), (ARKG), (GNOM), (BIB), and (HELX).